Trade CNS Pharmaceuticals, Inc. - CNSP CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.413
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.02224 %(-$4.45)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.02224%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position0.00001 %($0.00)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: 0.00001%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.02224 %
  (-$4.45)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: 0.00001 %
  ($0.00)

Key Stats

• Prev. Close: 5.0035
• Open: 5.2533
• 1-Year Change: -43.21%
• Day's Range: 4.8936 - 5.2533

Trade CNS Pharmaceuticals, Inc. - CNSP

About CNS Pharmaceuticals Inc

CNS Pharmaceuticals Inc. is a clinical pharmaceutical company. The Company is focused on development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The Company is developing its lead drug candidate, Berubicin for the treatment of glioblastoma. Glioblastoma are tumors that arise from astrocytes, which are star-shaped cells making up the supportive tissue of the brain. Berubicin is an anthracycline, a class of drugs that are among the chemotherapy drugs, which intercalates into Deoxyribonucleic acid (DNA) and interrupts topoisomerase II activity, resulting in the inhibition of DNA replication and repair, and RNA and protein synthesis. The Company is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, CNS Pharmaceuticals Inc revenues was not reported. Net loss increased 48% to $14M. Higher net loss reflects Research and development increase of 85% to $9.3M (expense), Selling/General/Admin Expense increase of 7% to $4.7M (expense), Interest expense increase from $3K to $9K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.57 to -$0.53.